BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15853161)

  • 1. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer.
    Swenson KK; Henly SJ; Shapiro AC; Schroeder LM
    Clin J Oncol Nurs; 2005 Apr; 9(2):177-84. PubMed ID: 15853161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK
    Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
    Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
    J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
    Limburg CE
    Oncol Nurs Forum; 2007 Jan; 34(1):55-63. PubMed ID: 17562633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy.
    Schwartz AL; Winters-Stone K; Gallucci B
    Oncol Nurs Forum; 2007 May; 34(3):627-33. PubMed ID: 17573321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for the management of weight and body composition changes in women with breast cancer.
    Rooney M; Wald A
    Clin J Oncol Nurs; 2007 Feb; 11(1):41-52. PubMed ID: 17441396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.
    Tham YL; Sexton K; Weiss HL; Elledge RM; Friedman LC; Kramer RM
    J Support Oncol; 2006 Jun; 4(6):295-8, 304. PubMed ID: 16805332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
    Rozenberg S; Carly B; Liebens F; Antoine C
    Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone loss and fracture risk associated with cancer therapy.
    Guise TA
    Oncologist; 2006; 11(10):1121-31. PubMed ID: 17110632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging and osteoporosis in breast and prostate cancer.
    VanderWalde A; Hurria A
    CA Cancer J Clin; 2011; 61(3):139-56. PubMed ID: 21543824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal breast cancer agents: implications for the primary care provider.
    Lyon DE; Roux G; Voll S
    J Am Acad Nurse Pract; 2006 Nov; 18(11):518-23. PubMed ID: 17064329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
    Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
    Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.